Cargando…

Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL

CD19-redirected chimeric antigen receptor (CAR) T cells have shown remarkable activity against B-cell cancers. While second-generation CARs induce complete remission in >80% of patients with acute lymphoblastic leukemia, similar monotherapy induces long-term remissions in only 26% of patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collins, McKensie A., Jung, In-Young, Zhao, Ziran, Apodaca, Kimberly, Kong, Weimin, Lundh, Stefan, Fraietta, Joseph A., Kater, Arnon P., Sun, Clare, Wiestner, Adrian, Melenhorst, J. Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010331/ https://www.ncbi.nlm.nih.gov/pubmed/36922932 http://dx.doi.org/10.1158/2767-9764.CRC-22-0200

Ejemplares similares

Engineering enhanced CAR T-cells for improved cancer therapy
por: Milone, Michael C., et al.
Publicado: (2021)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

Pathogenesis of CLL: the view from the lymph node
por: Wiestner, Adrian
Publicado: (2018)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Validating genomic tools for precision medicine in CLL: ERIC leads the way
por: Wiestner, Adrian
Publicado: (2021)

Insulin signaling pathways in lepidopteran ecdysone secretion
por: Smith, Wendy A., et al.
Publicado: (2014)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL
por: Sun, Clare, et al.
Publicado: (2021)

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
por: Efremov, Dimitar G., et al.
Publicado: (2012)

TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells
por: Collins, Sierra M., et al.
Publicado: (2023)

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
por: Omer, Bilal, et al.
Publicado: (2022)

CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
por: Long, Kristen B., et al.
Publicado: (2018)

Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
por: Quintarelli, Concetta, et al.
Publicado: (2018)

Distinct Costimulatory Molecules Are Required for the Induction of Effector and Memory Cytotoxic T Lymphocytes
por: Liu, Yang, et al.
Publicado: (1997)

Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection
por: Rosado-Sánchez, Isaac, et al.
Publicado: (2023)

Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
por: Smith, Richard, et al.
Publicado: (2023)

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
por: Dimitri, Alexander, et al.
Publicado: (2022)

Threading carbon nanotubes through a self-assembled nanotube
por: Ji, Mingyang, et al.
Publicado: (2019)

Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels
por: Wang, Wenliang, et al.
Publicado: (2020)

γδ T cell costimulatory ligands in antitumor immunity
por: McGraw, Joseph M., et al.
Publicado: (2022)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

Microemulsions: Breakthrough Electrolytes for Redox Flow Batteries
por: Barth, Brian A., et al.
Publicado: (2022)

Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
por: Bai, Zhiliang, et al.
Publicado: (2022)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
por: Haselager, Marco, et al.
Publicado: (2021)

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
por: Wang, Jinghua, et al.
Publicado: (2018)

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival
por: Haselager, Marco V., et al.
Publicado: (2023)

Costimulatory pathways in transplantation
por: Pilat, Nina, et al.
Publicado: (2011)

Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells
por: Kumari, Anita, et al.
Publicado: (2013)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
por: Zhang, Hui, et al.
Publicado: (2020)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells
por: Bai, Zhiliang, et al.
Publicado: (2021)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
por: Haselager, Marco V., et al.
Publicado: (2023)

Adaptive and Innate Cytotoxic Effectors in Chronic Lymphocytic Leukaemia (CLL) Subjects with Stable Disease
por: Rubino, Valentina, et al.
Publicado: (2023)

Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions
por: Sajman, Julia, et al.
Publicado: (2023)

A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors
por: Janssen, Jerry, et al.
Publicado: (2021)

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
por: Wutti-in, Yupanun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8pmvtg64ah1hj8g17u69qr3qqa